Anti-inflammatory Peptide Market Research Report By Mechanism of Action (NF-B Inhibition, JAK/STAT Inhibition, Interleukin Inhibition, TNF- Inhibition), By Indication (Rheumatoid Arthritis, Osteoarthritis, Gout, Multiple Sclerosis), By Source (Animal Origin, Plant Origin, Microbial Origin), By Route of Administration (Injections, Oral, Topical) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Forecast to 2032

Anti-inflammatory Peptide Market Overview:

As per MRFR analysis, the Anti-inflammatory Peptide Market Size was estimated at 4.91 (USD Billion) in 2022. The Anti-inflammatory Peptide Market Industry is expected to grow from 5.5(USD Billion) in 2023 to 15.2 (USD Billion) by 2032. The Anti-inflammatory Peptide Market CAGR (growth rate) is expected to be around 11.96% during the forecast period (2024 - 2032).

Key Anti-inflammatory Peptide Market Trends Highlighted

The Global Anti-Inflammatory Peptide Market is expected to grow due to increasing cases of inflammatory-related disorders, increasing efforts towards r&d and advancements in the biotechnological sector. Important market growth factors have been the awareness of being able to use peptides to modulate inflammation, an increasing number of peptides being developed that have better efficacy and selectivity, and the growing use of non-steroidal anti-inflammatory drugs (NSAIDs).

There are opportunities in the market for developing multi-functional peptides with anti-inflammatory and other therapeutic properties, broader use in different areas of medicine, and integration of peptides with drug delivery systems. Recent trends include using machine learning and AI to speed up peptide identification and optimisation processes, searching for natural sources of peptides with anti-inflammatory activity, and the development precision medicine based on the characteristics of the patient.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Anti-inflammatory Peptide Market Drivers

Rising Prevalence of Inflammatory Diseases

The increasing prevalence of inflammatory diseases such as arthritis, asthma, and inflammatory bowel disease primarily drives the global anti-inflammatory peptide market. As per the Arthritis Foundation, over 54 million adults in the United States have doctor-diagnosed arthritis, while the World Health Organization (WHO) estimates that asthma affects over 262 million people worldwide. These inflammatory conditions cause significant pain, discomfort, and disability, leading to a growing demand for effective treatments, including anti-inflammatory peptides.

Advancements in Biotechnology

Advancements in biotechnology have significantly contributed to the growth of the global anti-inflammatory peptide market. The development of recombinant DNA technology and genetic engineering techniques has enabled the production of highly specific and potent anti-inflammatory peptides. These peptides can be designed to target specific inflammatory pathways, offering greater efficacy and fewer side effects compared to traditional non-steroidal anti-inflammatory drugs (NSAIDs).Moreover, advances in peptide synthesis and delivery systems have improved the bioavailability and stability of anti-inflammatory peptides, further driving market growth.

Increased Focus on Personalized Medicine

The growing trend towards personalized medicine is another key factor fueling the growth of the Global Anti-inflammatory Peptide Market Industry. Personalized medicine involves tailoring treatments to the individual needs of patients based on their genetic profile and disease characteristics. Anti-inflammatory peptides offer significant potential for personalized medicine as they can be designed to target specific inflammatory pathways or biomarkers associated with different diseases.This approach can lead to more effective and targeted therapies, reducing the risk of adverse effects and improving patient outcomes.

Anti-inflammatory Peptide Market Segment Insights:

Anti-inflammatory Peptide Market Mechanism of Action Insights  

The Global Anti-inflammatory Peptide Market segmentation by Mechanism of Action includes NF-B Inhibition, JAK/STAT Inhibition, Interleukin Inhibition, and TNF- Inhibition. Among these, the NF-B Inhibition segment held the largest market share in 2023 and is expected to continue its dominance during the forecast period. The growth of this segment can be attributed to the increasing prevalence of inflammatory diseases, such as rheumatoid arthritis and Crohn's disease. The JAK/STAT Inhibition segment is also expected to witness significant growth during the forecast period, owing to the rising adoption of JAK inhibitors for the treatment of autoimmune diseases.The Global Anti-inflammatory Peptide Market data shows that the Interleukin Inhibition segment is expected to grow at a steady pace during the forecast period. This growth can be attributed to the increasing use of interleukin inhibitors for the treatment of inflammatory diseases, such as psoriasis and multiple sclerosis. The TNF-inhibition segment is also expected to witness moderate growth during the forecast period, owing to the increasing use of TNF inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis and Crohn's disease.The growth of the Global Anti-inflammatory Peptide Market is attributed to the increasing prevalence of inflammatory diseases, the rising adoption of targeted therapies, and the growing demand for personalized medicine. The market is also expected to benefit from the increasing investment in research and development activities by pharmaceutical companies.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Anti-inflammatory Peptide Market Indication Insights  

The global Anti-inflammatory Peptide Market is segmented into various indications, including Rheumatoid Arthritis, Osteoarthritis, Gout, and Multiple Sclerosis. Among these, Rheumatoid Arthritis accounted for the largest revenue share in 2023, owing to the high prevalence of the condition and the availability of effective treatments. The Osteoarthritis segment is also expected to witness significant growth due to the rising geriatric population, which is more susceptible to this condition. Gout and Multiple Sclerosis are other key indications that are driving the growth of the Anti Inflammatory Peptide Market.The increasing prevalence of these conditions, coupled with the growing demand for effective treatments, is expected to fuel the growth of this segment in the coming years.

Anti-inflammatory Peptide Market Source Insights  

The Global Anti-inflammatory Peptide Market segmentation by Source is categorized into Animal Origin, Plant Origin, and Microbial Origin. Among these segments, Animal Origin held the largest market share in 2023, accounting for around 45.0% of the Global Anti-inflammatory Peptide Market revenue. The increasing demand for animal-derived peptides drives the growth of this segment due to their high biological activity and specificity. Plant Origin is expected to witness significant growth over the forecast period, owing to the growing adoption of plant-based products and the rising prevalence of veganism.Microbial Origin is projected to grow at a steady pace, driven by the advancements in biotechnology and the increasing use of microbial peptides in therapeutic applications.

Anti-inflammatory Peptide Market Route of Administration Insights  

Injections accounted for the largest revenue share of the global Anti-inflammatory Peptide Market in 2023, and this trend is projected to continue during the forecast period. This dominance can be attributed to the high efficacy and targeted delivery of anti-inflammatory peptides via injections. Injections allow for precise administration of the therapeutic directly into the affected area or bloodstream, ensuring rapid onset of action and sustained therapeutic effects. Moreover, injections are suitable for treating various conditions, including rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease.Oral administration is another significant route of administration for anti-inflammatory peptides. Oral formulations offer convenience and ease of administration, making them suitable for long-term therapies. However, oral bioavailability of peptides can be limited due to degradation in the gastrointestinal tract. Research efforts are focused on developing novel delivery systems to enhance oral bioavailability and improve the efficacy of anti-inflammatory peptides. Topical administration of anti-inflammatory peptides is gaining traction due to its non-invasive nature and targeted delivery to the affected area.Topical formulations, such as creams, ointments, and gels, can effectively treat skin conditions, including psoriasis, eczema, and burns. They offer localized delivery of the therapeutic, minimizing systemic exposure and potential side effects.

Anti-inflammatory Peptide Market Regional Insights  

The Global Anti-inflammatory Peptide Market is segmented into North America, Europe, APAC, South America, and MEA. North America is expected to hold the largest market share in 2023, owing to the presence of a large number of pharmaceutical companies and research institutions, with a market value of 2.042 billion USD, rising to 5.186 billion USD by 2032. Europe is expected to be the second-largest market, with a value of 2.042 billion USD in 2023 and 5.024 billion USD in 2032, followed by APAC, which is expected to witness a market value of 0.766 billion USD in 2023 and grow to 3.369 billion USD by 2032. South America and MEA are expected to account for a smaller share of the global market, with South America valued at 0.278 billion USD in 2023 and 0.729 billion USD in 2032, and MEA at 0.371 billion USD in 2023 and 0.891 billion USD in 2032.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Anti-inflammatory Peptide Market Key Players And Competitive Insights:

Major players in the Anti-inflammatory Peptide Market are focusing on developing innovative products and expanding their product portfolio. Leading Anti-inflammatory Peptide Market players are also investing in research and development to improve the efficacy and safety of their products. The presence of a few large players and a number of small and medium-sized players characterizes the Anti-inflammatory Peptide Market industry. The competitive landscape of the Anti-inflammatory Peptide Market is expected to remain fragmented in the coming years, with the leading players continuing to dominate the market. However, the entry of new players and the expansion of existing players into new markets is expected to intensify competition in the Anti Inflammatory Peptide Market.A leading company in the Global Anti-inflammatory Peptide Market is Amgen. The company is a global leader in the development and manufacture of pharmaceuticals, including biologics. Amgen's Anti-inflammatory Peptide Market products include Enbrel, which is used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The company also markets Otezla, which is used to treat plaque psoriasis and psoriatic arthritis. Amgen is committed to research and development, and the company has a strong pipeline of new Anti-inflammatory Peptide Market products in development.A competitor company in the Global Anti-inflammatory Peptide Market is AbbVie. The company is a global leader in the development and manufacture of pharmaceuticals, including biologics. AbbVie's Anti-inflammatory Peptide Market products include Humira, which is used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The company also markets Skyrizi, which is used to treat plaque psoriasis and psoriatic arthritis. AbbVie is committed to research and development, and the company has a strong pipeline of new Anti-inflammatory Peptide Market products in development.

Key Companies in the Anti-inflammatory Peptide Market Include:

• Johnson Johnson


• GlaxoSmithKline


• Roche


• Bristol-Myers Squibb


• Novartis


• Celgene


• Amgen


• AbbVie


• Peptron


• Pfizer


• Bayer


• Sanofi


• Merck


• Eli Lilly and Company

Anti-inflammatory Peptide Market Industry Developments

The Anti-Inflammatory Peptide Market is poised to expand significantly over the forecast period, driven by the rising prevalence of chronic inflammatory diseases, increasing demand for targeted therapies, and advancements in peptide-based drug development. Key players in the market include Novartis, Amgen, Merck, and Pfizer. Recent developments include the approval of new anti-inflammatory peptide drugs, such as Amgen's Parsabiv and Chinook Therapeutics' BPR4 antagonist. Additionally, ongoing research into the role of peptides in immune regulation and inflammation is expected to fuel future market growth.

Anti-inflammatory Peptide Market Segmentation Insights

Anti-inflammatory Peptide Market Mechanism of Action Outlook

• NF-B Inhibition


• JAK/STAT Inhibition


• Interleukin Inhibition


• TNF- Inhibition

Anti-inflammatory Peptide Market Indication Outlook

• Rheumatoid Arthritis


• Osteoarthritis


• Gout


• Multiple Sclerosis

Anti-inflammatory Peptide Market Source Outlook

• Animal Origin


• Plant Origin


• Microbial Origin

Anti-inflammatory Peptide Market Route of Administration Outlook

• Injections


• Oral


• Topical

Anti-inflammatory Peptide Market Regional Outlook

• North America


• Europe


• South America


• Asia-Pacific


• Middle East and Africa